Bayer Granted FDA Breakthrough Therapy Designation for Non-Small Cell Lung Cancer Drug

BAY 2927088 is an oral, reversible small molecule tyrosine kinase inhibitor being analyzed for the treatment of unresectable or metastatic non-small cell lung cancer with tumors that have activating HER2 mutations.

Source link
#Bayer #Granted #FDA #Breakthrough #Therapy #Designation #NonSmall #Cell #Lung #Cancer #Drug